Top Back to top

Daratumumab for PRCA after alloSCT

Transplant Complications Working Party (TCWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Complications: non-infectious
Short title:
Dara for PRCA
Primary objective:
The goal of this study is to evaluate the efficacy and safety of daratumumab for PRCA after allogeneic transplantation.
Key inclusion criteria:
Principal investigator:
Nico Gagelmann
EBMT Study coordinator:
William Boreland
Study coordinator email: